Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Medicación anticolinérgica para la sialorrea inducida por neurolépticos no clozapina en pacientes con esquizofrenia

Información

DOI:
https://doi.org/10.1002/14651858.CD009546.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 19 diciembre 2013see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Esquizofrenia

Copyright:
  1. Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Adib Essali

    Correspondencia a: Psychiatry Centre, Modern Psychiatry Hospital, Damascus, Syrian Arab Republic

    [email protected]

    [email protected]

  • Anas Rihawi

    Internal Medicine, St.Elizabeth's Medical Center, Brighton, USA

  • Mohammad Altujjar

    Faculty of Medicine, Aleppo University, Aleppo, Syrian Arab Republic

  • Bishr Alhafez

    Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic

  • Amjad Tarboush

    Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic

  • Nahla Alhaj Hasan

    Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic

Contributions of authors

Adib Essali ‐ developed protocol and wrote review.

Nahla Alhaj Hasan ‐ developed protocol and wrote review.

Anas Rihawi ‐ developed protocol and wrote review.

Bishr Alhafez ‐ developed protocol and wrote review.

Amjad Tarboush ‐ developed protocol and wrote review.

Mohammad Fakhri Al‐tujjar ‐ help with selection of trials and data extraction.

Sources of support

Internal sources

  • Association for Evidence‐Based Medicine, Syrian Arab Republic.

    Training

External sources

  • No sources of support supplied

Declarations of interest

None.

Acknowledgements

The Cochrane Schizophrenia Group Editorial Base in Nottingham produces and maintains standard text for use in the Methods sections of their reviews. We have used this text as the basis of what appears here and have adapted it as required.

We would like to acknowledge the contribution of Maher Sharaf, who helped develop the protocol and assisted in writing the review.

Version history

Published

Title

Stage

Authors

Version

2013 Dec 19

Anticholinergic medication for non‐clozapine neuroleptic‐induced hypersalivation in people with schizophrenia

Review

Adib Essali, Anas Rihawi, Mohammad Altujjar, Bishr Alhafez, Amjad Tarboush, Nahla Alhaj Hasan

https://doi.org/10.1002/14651858.CD009546.pub2

2012 Feb 15

Anticholinergic medication for non‐clozapine neuroleptic‐induced hypersalivation in people with schizophrenia

Protocol

Adib Essali, Anas Rihawi, Maher Sharaf, Mohammad Fakhri Al‐tujjar, Bishr Alhafez, Amjad Tarboush, Nahla Alhaj Hasan

https://doi.org/10.1002/14651858.CD009546

Differences between protocol and review

None

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Humans;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Table 1. Prevalence of Increased Salivation, Short‐term Results (by 12 Weeks or Less) (adopted from Ozbilen 2009)

Compound

n

RCTs

% (95% CI)

Placebo

403

10

7.7 (5 to 11)

Clozapine

559

16

32.7 (29 to 37)

Zotepine

53

1

41.5 (29 to 55)

Zuclopenthixol hydrochloride

66

2

24.2 (16 to 36)

Haloperidol

1115

12

18.4 (16 to 21)

Thioridazine

66

2

15.2 (8 to 26)

Chlorpromazine

499

12

14.2 (11 to 18)

Trifluoperazine

44

6

13.6 (6 to 27)

Molindone

42

2

9.5 (4 to 22)

Bromperidol depot

27

1

3.7 (1 to 18)

Olanzapine

1857

5

8.2 (7 to 10)

Fluphenazine hydrochloride

110

2

8.2 (4 to 15)

Amisulpride

115

1

7.8 (4 to 14)

Sulpiride

154

6

7.1 (4 to 12)

Risperidone depot

317

2

5.7 (4 to 9)

Perphenazine

74

3

5.4 (2 to 13)

Risperidone

325

3

3.7 (2 to 6)
Figuras y tablas -
Table 1. Prevalence of Increased Salivation, Short‐term Results (by 12 Weeks or Less) (adopted from Ozbilen 2009)
Ir a la tabla de la revisión